Treatment of Hepatitis C with sofosbuvir/velpatasvir (Epclusa®)

Policy # 00514
Original Effective Date: 08/17/2016
Current Effective Date: 11/15/2017

Applies to all products administered or underwritten by Blue Cross and Blue Shield of Louisiana and its subsidiary, HMO Louisiana, Inc. (collectively referred to as the “Company”), unless otherwise provided in the applicable contract. Medical technology is constantly evolving, and we reserve the right to review and update Medical Policy periodically.

Note: Treatment of Hepatitis C with Triple Therapy (Ribavirin Plus Pegylated Interferon Alfa Plus telaprevir [Incivek®] or boceprevir [Victrelis®]) is addressed separately in medical policy 00373.

Note: Treatment of Hepatitis C with Dual Therapy (Ribavirin Plus Pegylated Interferon Alfa) is addressed separately in medical policy 00374.

Note: Pegylated Interferons (Pegasys®, PegIntron®) for Other (Non-Hepatitis C) Uses is addressed separately in medical policy 00375.

Note: Treatment of Hepatitis C with a simeprevir (Olysio®) Based Regimen is addressed separately in medical policy 00396.

Note: Treatment of Hepatitis C with a sofosbuvir (Sovaldi®) Based Regimen is addressed separately in medical policy 00397.

Note: Treatment of Hepatitis C with sofosbuvir/ledipasvir (Harvoni®) is addressed separately in medical policy 00455.

Note: Treatment of Hepatitis C with simeprevir (Olysio®) PLUS sofosbuvir (Sovaldi®) is addressed separately in medical policy 00457.

Note: Treatment of Hepatitis C with ombitasvir, paritaprevir, ritonavir, and dasabuvir (Viekira Pak®) is addressed separately in medical policy 00462.

Note: Treatment of Hepatitis C with ombitasvir, paritaprevir, and ritonavir (Technivie®) is addressed separately in medical policy 00478.

Note: Treatment of Hepatitis C with daclatasvir (Daklinza™) PLUS sofosbuvir (Sovaldi®) is addressed separately in medical policy 00479.

Note: Treatment of Hepatitis C with elbasvir and grazoprevir (Zepatier™) is addressed separately in medical policy 00509.

Note: Treatment of Hepatitis C with glecaprevir/pibrentasvir (Mavyret™) is addressed separately in medical policy 00593.

©2017 Blue Cross and Blue Shield of Louisiana

Blue Cross and Blue Shield of Louisiana is an independent licensee of the Blue Cross and Blue Shield Association and incorporated as Louisiana Health Service & Indemnity Company.

No part of this publication may be reproduced, stored in a retrieval system, or transmitted, in any form or by any means, electronic, mechanical, photocopying, or otherwise, without permission from Blue Cross and Blue Shield of Louisiana.
Treatment of Hepatitis C with sofosbuvir/velpatasvir (Epclusa®)

Policy # 00514
Original Effective Date: 08/17/2016
Current Effective Date: 11/15/2017

Note: Treatment of Hepatitis C with sofosbuvir/velpatasvir/voxilaprevir (Vosevi™) is addressed separately in medical policy 00594.

When Services May Be Eligible for Coverage
Coverage for eligible medical treatments or procedures, drugs, devices or biological products may be provided only if:
- Benefits are available in the member’s contract/certificate, and
- Medical necessity criteria and guidelines are met.

Based on review of available data, the Company may consider sofosbuvir/velpatasvir (Epclusa®)‡ for the treatment of individuals with chronic hepatitis C virus (HCV) to be eligible for coverage.

Genotypes 1, 4, 5, and 6
Patient Selection Criteria
Based on review of available data, the Company may consider sofosbuvir/velpatasvir (Epclusa) for the treatment of HCV when the following criteria are met:
- Patient has a diagnosis of chronic hepatitis C virus (HCV) genotypes 1, 4, 5, or 6; AND
- Patient has NOT failed prior therapy with drugs such as elabasvir/grazoprevir (Zepatier™), sofosbuvir/ledipasvir (Harvoni®), ombitasvir, paritaprevir, ritonavir, dasabuvir (Viekira Pak/XR®), daclatasvir (Daklinza™), sofosbuvir (Sovaldi®), gelcaprevir/pibrentasvir (Mavyret™), sofosbuvir/velpatasvir/voxilaprevir (Vosevi™), or ombitasvir, paritaprevir, ritonavir (Technivie®); AND
- Patient meets the following definitions and adheres to the timeframes for treatment (including concomitant medications):

<table>
<thead>
<tr>
<th>Patient Population</th>
<th>Recommended Treatment Regimen</th>
</tr>
</thead>
<tbody>
<tr>
<td>Treatment naïve and treatment experienced¹ without cirrhosis and with compensated cirrhosis (Child Pugh A)</td>
<td>Epclusa for 12 weeks</td>
</tr>
<tr>
<td>Treatment naïve and treatment experienced¹ with decompensated cirrhosis (Child Pugh B and C)</td>
<td>Epclusa PLUS ribavirin for 12 weeks</td>
</tr>
</tbody>
</table>

¹Patients in trials were treatment experienced with peginterferon/ribavirin OR peginterferon/ribavirin plus a protease inhibitor (Incivek, Victrilis, Olysio)

When Services Are Considered Investigational
Coverage is not available for investigational medical treatments or procedures, drugs, devices or biological products.
Based on review of available data, the Company considers sofosbuvir/velpatasvir (Epclusa) when patient selection criteria are not met to be investigational.*

**Genotypes 2 and 3**

**Patient Selection Criteria**

Based on review of available data, the Company may consider sofosbuvir/velpatasvir (Epclusa) for the treatment of hepatitis C virus (HCV) when the following criteria are met:

- Patient has a diagnosis of chronic hepatitis C virus (HCV) genotypes 2 or 3; AND
- Epclusa (if approved) will be used as follows:

<table>
<thead>
<tr>
<th><strong>Tx Naive</strong></th>
<th><strong>Recommended Treatment Regimen</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>Patients withOUT cirrhosis</td>
<td>Epclusa for 12 weeks</td>
</tr>
<tr>
<td>Patients WITH compensated cirrhosis (Child Pugh A)</td>
<td></td>
</tr>
<tr>
<td>Patients WITH DEcompensated cirrhosis (Child Pugh B and C)</td>
<td>Epclusa PLUS ribavirin for 12 weeks</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th><strong>Tx Experienced</strong></th>
<th><strong>Recommended Treatment Regimen</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>Genotype 2, pegylated interferon/ribavirin failures, withOUT cirrhosis or WITH compensated cirrhosis (Child Pugh A)</td>
<td>Epclusa for 12 weeks</td>
</tr>
<tr>
<td>Genotype 2, Sovaldi PLUS ribavirin failures, WITH compensated cirrhosis (Child Pugh A) or without cirrhosis</td>
<td>Epclusa for 12 weeks*</td>
</tr>
<tr>
<td>Genotype 3, pegylated interferon/ribavirin failures, without cirrhosis</td>
<td>Epclusa for 12 weeks</td>
</tr>
<tr>
<td>Genotype 3, pegylated interferon/ribavirin failures, WITH compensated cirrhosis (Child Pugh A)</td>
<td>Epclusa PLUS ribavirin for 12 weeks*</td>
</tr>
<tr>
<td>Genotype 2 or 3 patients with DEcompensated cirrhosis (Child Pugh B/C)</td>
<td>Epclusa PLUS ribavirin for 12 weeks</td>
</tr>
</tbody>
</table>

*These regimens are considered “off-label” however they are mentioned in the AASLD (American Association for the Study of Liver Diseases) Hepatitis C Guidelines. If the requirements for the addition of ribavirin (where applicable) is not met, these will be denied as not medically necessary** as they are a requirement beyond the package insert.
Treatment of Hepatitis C with sofosbuvir/velpatasvir (Epclusa®)

Policy # 00514
Original Effective Date: 08/17/2016
Current Effective Date: 11/15/2017

Background/Overview
Epclusa is a fixed dose combination of sofosbuvir 400 mg, a HCV nucleotide analog NS5B polymerase inhibitor, and velpatasvir 100 mg, a HCV NS5A inhibitor, approved for the treatment of adult patients with chronic HCV genotypes 1, 2, 3, 4, 5, or 6 infection. The dosage is 1 tablet per day for 12 weeks of therapy. Depending on the indication, ribavirin may or may not need to be taken concomitantly.

Hepatitis C
Hepatitis C is the most common blood borne pathogen. In the US, there are approximately 5.2 million people chronically infected with hepatitis C. Hepatitis C, a single-stranded ribonucleic acid (RNA) virus, is genetically complex with several recognized genotypes. Genotypes 1, 2, and 3 are the most frequently encountered genotypes worldwide.

Drug regimens have evolved quite a bit over the past few years in this class. It is beyond the scope of this policy to delve into the entire timeline of approvals, however a brief overview will provide an idea of the evolution of these drugs. The earlier regimens contained ribavirin and interferon/pegylated interferons. The next wave of products brought NS3/4A protease inhibitors to market such as Incivek and Victrelis. After that, an NS5B polymerase inhibitor was approved (Sovaldi). Following the release of Sovaldi, a drug was approved that contained a combination NS5A inhibitor and NS5B polymerase inhibitor combination (Harvoni). Drugs approved up until that point in time mainly treated genotype 1 hepatitis C virus. After these drugs were approved, a multitude of other drugs were approved (Viekira/XR, Zepatier, Daklinza, etc). As drugs continue to be FDA approved in this space, the range of genotypes that can be treated increases. The latest wave of drugs includes pangenotypic products such as Epclusa, Mavyret, and Vosevi. For more information on each individual drug, please see the product’s package insert or refer to their respective medical policy.

Epclusa has been integrated into the American Association for the Study of Liver Diseases (AASLD) guidelines in various scenarios for the treatment of HCV, however it should be noted that these guidelines are receiving constant updates as new products are approved.

FDA or Other Governmental Regulatory Approval
U.S. Food and Drug Administration (FDA)
Epclusa was approved in June of 2016 for the treatment of adult patients with chronic HCV genotypes 1, 2, 3, 4, 5, and 6.

Rationale/Source
This medical policy was developed through consideration of peer-reviewed medical literature generally recognized by the relevant medical community, U.S. FDA approval status, nationally accepted standards of medical practice and accepted standards of medical practice in this community, Blue Cross and Blue Shield Association technology assessment program (TEC) and other non-affiliated technology evaluation centers, reference to federal regulations, other plan medical policies, and accredited national guidelines.

©2017 Blue Cross and Blue Shield of Louisiana

Blue Cross and Blue Shield of Louisiana is an independent licensee of the Blue Cross and Blue Shield Association and incorporated as Louisiana Health Service & Indemnity Company.

No part of this publication may be reproduced, stored in a retrieval system, or transmitted, in any form or by any means, electronic, mechanical, photocopying, or otherwise, without permission from Blue Cross and Blue Shield of Louisiana.
Treatment of Hepatitis C with sofosbuvir/velpatasvir (Epclusa®)

Policy # 00514
Original Effective Date: 08/17/2016
Current Effective Date: 11/15/2017

With/Without Compensated Cirrhosis
ABSTRAL-1 was a randomized, double-blind, placebo-controlled trial that evaluated 12 weeks of treatment with Epclusa vs. 12 weeks of placebo in subjects with genotype 1, 2, 4, 5, or 6 HCV infection. Subjects in this study either had no cirrhosis or had compensated cirrhosis. The overall SVR12 for all genotypes was 99%. For genotype 1, the SVR was 98%, for genotype 2, 100%, genotype 4, 100%, genotype 5, 97%, and genotype 6 was 100%. In this trial, there were no on-treatment virologic failures and <1% relapses.

ABSTRAL-2 was a randomized, open-label trial that evaluated 12 weeks of therapy with Epclusa versus treatment with Sovaldi plus ribavirin in patients with genotype 2 HCV. This study included those that were both treatment naïve and treatment experienced. This trial also included subjects without cirrhosis or with compensated cirrhosis. The SVR12 in the Epclusa group was 99% versus 94% in the Sovaldi plus ribavirin group. There were no on-treatment virologic failures in either groups. There were no relapses in the Epclusa group versus 5% of the population relapsing in the Sovaldi plus ribavirin group.

ABSTRAL-3 was a randomized, open-label trial that studied 12 weeks of Epclusa versus 24 weeks of Sovaldi plus ribavirin in patients with genotype 3 HCV. There were both treatment naïve and treatment experienced subjects in this trial. This trial also included subjects without cirrhosis or with compensated cirrhosis. The SVR12 in this Epclusa group was 95% versus 80% in the Sovaldi plus ribavirin group. There were no on-treatment virologic failures in the Epclusa group versus <1% in the Sovaldi plus ribavirin group. There was a 4% relapse rate in the Epclusa group versus a 14% rate in the Sovaldi plus ribavirin group.

Just to note, Epclusa did not include studies in the package insert for those that have failed a sofosbuvir containing regimen. Those patients are likely better suited to receive Harvoni per the AASLD guidelines.

Decompensated Cirrhosis
ABSTRAL-4 was a randomized, open-label trial in subjects with genotypes 1, 2, 3, 4, 5, or 6 with decompensated cirrhosis. Subjects were randomized to Epclusa for 12 weeks or Epclusa plus ribavirin for 12 weeks or Epclusa for 24 weeks. The Epclusa plus ribavirin regimen had numerically higher SVR rates than the other two regimens. The overall SVR12 for all genotypes was 94% with a 3% virologic failure rate.

References

Policy History
Original Effective Date: 08/17/2016
Current Effective Date: 11/15/2017
08/04/2016 Medical Policy Committee review
08/17/2016 Medical Policy Implementation Committee approval. New Policy.
08/03/2017 Medical Policy Committee review
08/23/2017 Medical Policy Implementation Committee approval. No change to coverage.

©2017 Blue Cross and Blue Shield of Louisiana

Blue Cross and Blue Shield of Louisiana is an independent licensee of the Blue Cross and Blue Shield Association and incorporated as Louisiana Health Service & Indemnity Company.

No part of this publication may be reproduced, stored in a retrieval system, or transmitted, in any form or by any means, electronic, mechanical, photocopying, or otherwise, without permission from Blue Cross and Blue Shield of Louisiana.
Treatment of Hepatitis C with sofosbuvir/velpatasvir (Epclusa®)

Policy #  00514
Original Effective Date:  08/17/2016
Current Effective Date:  11/15/2017

11/02/2017  Medical Policy Committee review
11/15/2017  Medical Policy Implementation Committee approval. Removed the requirement for Harvoni first prior to Epclusa for genotypes 1, 4, 5, 6. Updated background info.

Next Scheduled Review Date:  11/2018

*Investigational – A medical treatment, procedure, drug, device, or biological product is Investigational if the effectiveness has not been clearly tested and it has not been incorporated into standard medical practice. Any determination we make that a medical treatment, procedure, drug, device, or biological product is Investigational will be based on a consideration of the following:

A. Whether the medical treatment, procedure, drug, device, or biological product can be lawfully marketed without approval of the U.S. FDA and whether such approval has been granted at the time the medical treatment, procedure, drug, device, or biological product is sought to be furnished; or

B. Whether the medical treatment, procedure, drug, device, or biological product requires further studies or clinical trials to determine its maximum tolerated dose, toxicity, safety, effectiveness, or effectiveness as compared with the standard means of treatment or diagnosis, must improve health outcomes, according to the consensus of opinion among experts as shown by reliable evidence, including:
   1. Consultation with the Blue Cross and Blue Shield Association technology assessment program (TEC) or other nonaffiliated technology evaluation center(s);
   2. Credible scientific evidence published in peer-reviewed medical literature generally recognized by the relevant medical community; or
   3. Reference to federal regulations.

**Medically Necessary (or “Medical Necessity”) - Health care services, treatment, procedures, equipment, drugs, devices, items or supplies that a Provider, exercising prudent clinical judgment, would provide to a patient for the purpose of preventing, evaluating, diagnosing or treating an illness, injury, disease or its symptoms, and that are:

A. In accordance with nationally accepted standards of medical practice;

B. Clinically appropriate, in terms of type, frequency, extent, level of care, site and duration, and considered effective for the patient's illness, injury or disease; and

C. Not primarily for the personal comfort or convenience of the patient, physician or other health care provider, and not more costly than an alternative service or sequence of services at least as likely to produce equivalent therapeutic or diagnostic results as to the diagnosis or treatment of that patient's illness, injury or disease.

For these purposes, “nationally accepted standards of medical practice” means standards that are based on credible scientific evidence published in peer-reviewed medical literature generally recognized by the relevant medical community, Physician Specialty Society recommendations and the views of Physicians practicing in relevant clinical areas and any other relevant factors.

‡ Indicated trademarks are the registered trademarks of their respective owners.

NOTICE: Medical Policies are scientific based opinions, provided solely for coverage and informational purposes. Medical Policies should not be construed to suggest that the Company recommends, advocates, requires, encourages, or discourages any particular treatment, procedure, or service, or any particular course of treatment, procedure, or service.